Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
BC1 cell line
Bria-OTS regimen and CPI (tislelizumab)
+1 more
Locations
1
United States
Sarcoma Oncology Center
Santa Monica, California, United States
Start Date
May 29, 2024
Primary Completion Date
April 30, 2025
Completion Date
October 30, 2025
Last Updated
August 26, 2024
NCT04541381
NCT05468034
NCT03137095
NCT04852887
NCT07547774
NCT06393374
Lead Sponsor
BriaCell Therapeutics Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions